<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)

<i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli<...

Full description

Bibliographic Details
Main Authors: Artur Muszyński, Kol A. Zarember, Christian Heiss, Joseph Shiloach, Lars J. Berg, John Audley, Arina Kozyr, David E. Greenberg, Steven M. Holland, Harry L. Malech, Parastoo Azadi, Russell W. Carlson, John I. Gallin
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/7/3303
id doaj-7742a9e28acd472eb3687d321e9e745a
record_format Article
spelling doaj-7742a9e28acd472eb3687d321e9e745a2021-03-25T00:01:06ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-03-01223303330310.3390/ijms22073303<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)Artur Muszyński0Kol A. Zarember1Christian Heiss2Joseph Shiloach3Lars J. Berg4John Audley5Arina Kozyr6David E. Greenberg7Steven M. Holland8Harry L. Malech9Parastoo Azadi10Russell W. Carlson11John I. Gallin12Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USABiotechnology Core, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USAComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USALaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA<i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli</i>, i.e., cytokine production in human blood requires 10–100 times more <i>G. bethesdensis</i> CFU/mL than <i>E. coli</i>. To better understand the pathogenicity of <i>G. bethesdensis</i>, we isolated its lipopolysaccharide (<i>Gb</i>LPS) and characterized its lipid A. Unlike with typical <i>Enterobacteriaceae</i>, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Man<i>p</i>-(1→4)-β-Glc<i>p</i>N3N-(1→6)-α-Glc<i>p</i>N-(1⇿1)-α-Glc<i>p</i>A tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of <i>Gb</i>LPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of <i>Gb</i>Ko–lipidA compared to <i>E. coli</i> lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the <i>G.bethesdensis</i> Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides.https://www.mdpi.com/1422-0067/22/7/3303lipopolysaccharidelipid AGram-negative pathogen, immunodeficiency
collection DOAJ
language English
format Article
sources DOAJ
author Artur Muszyński
Kol A. Zarember
Christian Heiss
Joseph Shiloach
Lars J. Berg
John Audley
Arina Kozyr
David E. Greenberg
Steven M. Holland
Harry L. Malech
Parastoo Azadi
Russell W. Carlson
John I. Gallin
spellingShingle Artur Muszyński
Kol A. Zarember
Christian Heiss
Joseph Shiloach
Lars J. Berg
John Audley
Arina Kozyr
David E. Greenberg
Steven M. Holland
Harry L. Malech
Parastoo Azadi
Russell W. Carlson
John I. Gallin
<i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
International Journal of Molecular Sciences
lipopolysaccharide
lipid A
Gram-negative pathogen, immunodeficiency
author_facet Artur Muszyński
Kol A. Zarember
Christian Heiss
Joseph Shiloach
Lars J. Berg
John Audley
Arina Kozyr
David E. Greenberg
Steven M. Holland
Harry L. Malech
Parastoo Azadi
Russell W. Carlson
John I. Gallin
author_sort Artur Muszyński
title <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
title_short <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
title_full <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
title_fullStr <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
title_full_unstemmed <i>Granulibacter bethesdensis</i>, a Pathogen from Patients with Chronic Granulomatous Disease, Produces a Penta-Acylated Hypostimulatory Glycero-d-talo-oct-2-ulosonic Acid–Lipid A Glycolipid (Ko-Lipid A)
title_sort <i>granulibacter bethesdensis</i>, a pathogen from patients with chronic granulomatous disease, produces a penta-acylated hypostimulatory glycero-d-talo-oct-2-ulosonic acid–lipid a glycolipid (ko-lipid a)
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-03-01
description <i>Granulibacter bethesdensis</i> can infect patients with chronic granulomatous disease, an immunodeficiency caused by reduced phagocyte NADPH oxidase function. Intact <i>G. bethesdensis</i> (<i>Gb</i>) is hypostimulatory compared to <i>Escherichia coli</i>, i.e., cytokine production in human blood requires 10–100 times more <i>G. bethesdensis</i> CFU/mL than <i>E. coli</i>. To better understand the pathogenicity of <i>G. bethesdensis</i>, we isolated its lipopolysaccharide (<i>Gb</i>LPS) and characterized its lipid A. Unlike with typical <i>Enterobacteriaceae</i>, the release of presumptive Gb lipid A from its LPS required a strong acid. NMR and mass spectrometry demonstrated that the carbohydrate portion of the isolated glycolipid consists of α-Man<i>p</i>-(1→4)-β-Glc<i>p</i>N3N-(1→6)-α-Glc<i>p</i>N-(1⇿1)-α-Glc<i>p</i>A tetra-saccharide substituted with five acyl chains: the amide-linked N-3′ 14:0(3-OH), N-2′ 16:0(3-O16:0), and N-2 18:0(3-OH) and the ester-linked O-3 14:0(3-OH) and 16:0. The identification of glycero-d-talo-oct-2-ulosonic acid (Ko) as the first constituent of the core region of the LPS that is covalently attached to GlcpN3N of the lipid backbone may account for the acid resistance of <i>Gb</i>LPS. In addition, the presence of Ko and only five acyl chains may explain the >10-fold lower proinflammatory potency of <i>Gb</i>Ko–lipidA compared to <i>E. coli</i> lipid A, as measured by cytokine induction in human blood. These unusual structural properties of the <i>G.bethesdensis</i> Ko–lipid A glycolipid likely contribute to immune evasion during pathogenesis and resistance to antimicrobial peptides.
topic lipopolysaccharide
lipid A
Gram-negative pathogen, immunodeficiency
url https://www.mdpi.com/1422-0067/22/7/3303
work_keys_str_mv AT arturmuszynski igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT kolazarember igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT christianheiss igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT josephshiloach igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT larsjberg igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT johnaudley igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT arinakozyr igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT davidegreenberg igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT stevenmholland igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT harrylmalech igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT parastooazadi igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT russellwcarlson igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
AT johnigallin igranulibacterbethesdensisiapathogenfrompatientswithchronicgranulomatousdiseaseproducesapentaacylatedhypostimulatoryglycerodtalooct2ulosonicacidlipidaglycolipidkolipida
_version_ 1724204305110532096